Prudential Financial Inc. purchased a new stake in shares of Chimerix Inc (NASDAQ:CMRX) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 24,138 shares of the biopharmaceutical company’s stock, valued at approximately $104,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in CMRX. Acadian Asset Management LLC lifted its stake in shares of Chimerix by 106.1% in the first quarter. Acadian Asset Management LLC now owns 482,557 shares of the biopharmaceutical company’s stock worth $1,013,000 after buying an additional 248,401 shares in the last quarter. Marshall Wace LLP bought a new position in Chimerix during the first quarter valued at approximately $166,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in Chimerix by 23.2% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 373,876 shares of the biopharmaceutical company’s stock valued at $785,000 after purchasing an additional 70,481 shares during the period. Dimensional Fund Advisors LP lifted its position in Chimerix by 2.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,612,871 shares of the biopharmaceutical company’s stock valued at $6,715,000 after purchasing an additional 56,347 shares during the period. Finally, Wells Fargo & Company MN lifted its position in Chimerix by 82.5% during the second quarter. Wells Fargo & Company MN now owns 60,574 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 27,378 shares during the period. Institutional investors own 63.43% of the company’s stock.
A number of research analysts recently weighed in on CMRX shares. HC Wainwright increased their price objective on shares of Chimerix from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. ValuEngine upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a research report on Monday. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $4.00.
Chimerix (NASDAQ:CMRX) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.18). Chimerix had a negative net margin of 729.02% and a negative return on equity of 38.70%. The business had revenue of $1.44 million for the quarter, compared to analysts’ expectations of $2.30 million. Sell-side analysts anticipate that Chimerix Inc will post -1.1 earnings per share for the current fiscal year.
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix Inc (NASDAQ:CMRX).
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.